Table 2.

Observed Response Rate, Progression-Free Survival, and Overall Survival Based on Time to 2L ICI Initiation Stratified to less than 3 Months Versus 3–6 Months Versus more than 6 Months Since Starting Platinum-Based Chemotherapy.

<3 months, 3–6 months, >6 months
	Observed Response Rate (ORR)
Time to 2L ICI	N	ORR, % (95% CI)	Unadjusted OR (95% CI)	Adjusted OR (95% CI)
<3 months	31	13(5–26)	0.44 (0.12–1.26)	0.62 (0.15–1.97)
3–6 months	72	28(18–40)	1.15 (0.59–2.25)	1.28 (0.61–2.63)
>6 months	112	25(18–34)	Reference	Reference
	Progression-Free Survival (PFS)
Time to 2L ICI	N	Med. PFS, months (95% CI)	Unadjusted HR (95% CI)	Adjusted HR (95% CI)
<3 months	31	3(2–4)	1.88 (1.21–2.91)	1.64 (1.02–2.63)
3–6 months	71	4(3–6)	1.03 (0.74–1.44)	1.08 (0.75–1.54)
>6 months	113	5(4–7)	Reference	Reference
	Overall Survival (OS)
Time to 2L ICI	N	Med. OS, months (95% CI)	Unadjusted HR (95% CI)	Adjusted HR (95% CI)
<3 months	31	4(3–8)	2.07 (1.33–3.23)	1.77 (1.10–2.84)
3–6 months	73	9(5–19)	1.12 (0.79–1.60)	1.07 (0.74–1.57)
>6 months	115	14(9–18)	Reference	Reference